Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors

NCT03995901 is registered in ClinicalTrials.gov with Talaris Therapeutics Inc. as lead sponsor.

NCT NCT03995901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03995901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors
Lead sponsor
Talaris Therapeutics Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 25, 2019
Completion date
February 16, 2023
Enrollment
15 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

transplanted organ rejection